- Home
- STG vs EPIX Comparison
STG vs EPIX Comparison
Compare STG & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STG
- EPIX
- Stock Information
- Founded
- STG 2003
- EPIX 2009
- Country
- STG China
- EPIX Canada
- Employees
- STG N/A
- EPIX N/A
- Industry
- STG Other Consumer Services
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- STG Real Estate
- EPIX Health Care
- Exchange
- STG Nasdaq
- EPIX Nasdaq
- Market Cap
- STG 83.8M
- EPIX 73.5M
- IPO Year
- STG 2018
- EPIX N/A
- Fundamental
- Price
- STG $6.45
- EPIX $1.65
- Analyst Decision
- STG
- EPIX Hold
- Analyst Count
- STG 0
- EPIX 3
- Target Price
- STG N/A
- EPIX $2.00
- AVG Volume (30 Days)
- STG 4.7K
- EPIX 286.3K
- Earning Date
- STG 11-22-2024
- EPIX 02-11-2025
- Dividend Yield
- STG N/A
- EPIX N/A
- EPS Growth
- STG N/A
- EPIX N/A
- EPS
- STG 4.57
- EPIX N/A
- Revenue
- STG $292,030,936.00
- EPIX N/A
- Revenue This Year
- STG N/A
- EPIX N/A
- Revenue Next Year
- STG N/A
- EPIX N/A
- P/E Ratio
- STG $1.46
- EPIX N/A
- Revenue Growth
- STG N/A
- EPIX N/A
- 52 Week Low
- STG $4.25
- EPIX $1.40
- 52 Week High
- STG $12.55
- EPIX $11.67
- Technical
- Relative Strength Index (RSI)
- STG 49.04
- EPIX 25.75
- Support Level
- STG $6.10
- EPIX $1.63
- Resistance Level
- STG $6.68
- EPIX $1.74
- Average True Range (ATR)
- STG 0.30
- EPIX 0.06
- MACD
- STG 0.04
- EPIX 0.10
- Stochastic Oscillator
- STG 63.95
- EPIX 12.82
About STG Sunlands Technology Group
Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.